Recent Preclinical and Clinical Progress in Liposomal Doxorubicin
Doxorubicin (DOX) is a potent anti-cancer agent that has garnered great interest in research due to its high efficacy despite dose-limiting toxicities. Several strategies have been exploited to enhance the efficacy and safety profile of DOX. Liposomes are the most established approach. Despite the i...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2023-03-01
|
| Serie: | Pharmaceutics |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/1999-4923/15/3/893 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|